Showing 37 to 48 of 54 results
Leqembi's Varied Efficacy in Alzheimer's Treatment Highlighted by Patient Case
Sue Bell, diagnosed with early-stage Alzheimer's in 2019, participated in a Leqembi clinical trial from 2020 to 2024, experiencing varied treatment benefits before discontinuing due to declining efficacy, highlighting the drug's limitations despite its approval in 2023.
Leqembi's Varied Efficacy in Alzheimer's Treatment Highlighted by Patient Case
Sue Bell, diagnosed with early-stage Alzheimer's in 2019, participated in a Leqembi clinical trial from 2020 to 2024, experiencing varied treatment benefits before discontinuing due to declining efficacy, highlighting the drug's limitations despite its approval in 2023.
Progress
44% Bias Score
mRNA Vaccine Shows Promise in Extending Survival for Early-Stage Pancreatic Cancer
A clinical trial at Memorial Sloan Kettering successfully used a customized mRNA vaccine alongside surgery and chemotherapy to treat early-stage pancreatic cancer, resulting in significantly extended survival time for eight of sixteen patients who showed strong immune responses and only two recurren...
mRNA Vaccine Shows Promise in Extending Survival for Early-Stage Pancreatic Cancer
A clinical trial at Memorial Sloan Kettering successfully used a customized mRNA vaccine alongside surgery and chemotherapy to treat early-stage pancreatic cancer, resulting in significantly extended survival time for eight of sixteen patients who showed strong immune responses and only two recurren...
Progress
40% Bias Score
Promising Phase 1 Results for Personalized Kidney Cancer Vaccine NeoVax
A phase 1 trial of NeoVax, a personalized cancer vaccine for kidney cancer, showed promising results in 9 patients, with all remaining disease-free after nearly three years; the vaccine induced a significant increase in T cells, highlighting its potential to prevent recurrence.
Promising Phase 1 Results for Personalized Kidney Cancer Vaccine NeoVax
A phase 1 trial of NeoVax, a personalized cancer vaccine for kidney cancer, showed promising results in 9 patients, with all remaining disease-free after nearly three years; the vaccine induced a significant increase in T cells, highlighting its potential to prevent recurrence.
Progress
40% Bias Score
Inavolisib Improves Outcomes in Pik3ca-Mutated Breast Cancer
A clinical trial (Inavo120) demonstrated that inavolisib, combined with palbociclib and fulvestrant, significantly improved progression-free and overall survival in 325 patients with hormone receptor-positive, HER2-negative, Pik3ca-mutated breast cancer compared to the standard therapy; the FDA appr...
Inavolisib Improves Outcomes in Pik3ca-Mutated Breast Cancer
A clinical trial (Inavo120) demonstrated that inavolisib, combined with palbociclib and fulvestrant, significantly improved progression-free and overall survival in 325 patients with hormone receptor-positive, HER2-negative, Pik3ca-mutated breast cancer compared to the standard therapy; the FDA appr...
Progress
40% Bias Score
Personalized Cancer Vaccine Shows Promise in Advanced Kidney Cancer
A small study of nine patients with advanced kidney cancer showed promising results using a personalized vaccine targeting neoantigens; after three years, all patients remained cancer-free, suggesting a new approach to treating this challenging disease.
Personalized Cancer Vaccine Shows Promise in Advanced Kidney Cancer
A small study of nine patients with advanced kidney cancer showed promising results using a personalized vaccine targeting neoantigens; after three years, all patients remained cancer-free, suggesting a new approach to treating this challenging disease.
Progress
44% Bias Score
Omega-3 Supplementation Slows Biological Aging in Clinical Trial
A three-year Swiss clinical trial of nearly 800 people over 70 found that daily omega-3 supplementation slowed biological aging by three months, an effect boosted to four months by adding vitamin D and exercise; this also reduced pre-frailty by 39% and invasive cancers by 61%.
Omega-3 Supplementation Slows Biological Aging in Clinical Trial
A three-year Swiss clinical trial of nearly 800 people over 70 found that daily omega-3 supplementation slowed biological aging by three months, an effect boosted to four months by adding vitamin D and exercise; this also reduced pre-frailty by 39% and invasive cancers by 61%.
Progress
40% Bias Score
Personalized mRNA Vaccine Shows Promise Against Pancreatic Cancer
A small study shows a personalized mRNA vaccine may significantly improve pancreatic cancer survival rates by generating long-lasting T cells that target cancer cells; half the participants who had a strong immune response remained cancer-free for over three years, far exceeding typical survival rat...
Personalized mRNA Vaccine Shows Promise Against Pancreatic Cancer
A small study shows a personalized mRNA vaccine may significantly improve pancreatic cancer survival rates by generating long-lasting T cells that target cancer cells; half the participants who had a strong immune response remained cancer-free for over three years, far exceeding typical survival rat...
Progress
40% Bias Score
Personalized mRNA Vaccines Show Promise in Pancreatic Cancer Treatment
A phase 1 clinical trial shows personalized mRNA vaccines generated a durable T-cell response in 50% of 16 patients with operable pancreatic cancer, lasting nearly eight years post-surgery, offering a potential new treatment for this deadly disease.
Personalized mRNA Vaccines Show Promise in Pancreatic Cancer Treatment
A phase 1 clinical trial shows personalized mRNA vaccines generated a durable T-cell response in 50% of 16 patients with operable pancreatic cancer, lasting nearly eight years post-surgery, offering a potential new treatment for this deadly disease.
Progress
44% Bias Score
Weekly Semaglutide Shows Promise in Reducing Alcohol Consumption
A JAMA Psychiatry study shows weekly semaglutide significantly reduced alcohol cravings and heavy drinking days in 48 adults with alcohol use disorder, with nearly 40% of the semaglutide group reporting no heavy drinking days in the final month versus 20% in the placebo group.
Weekly Semaglutide Shows Promise in Reducing Alcohol Consumption
A JAMA Psychiatry study shows weekly semaglutide significantly reduced alcohol cravings and heavy drinking days in 48 adults with alcohol use disorder, with nearly 40% of the semaglutide group reporting no heavy drinking days in the final month versus 20% in the placebo group.
Progress
40% Bias Score
Personalized Cancer Vaccine Shows Promise in Treating Advanced Kidney Cancer
A new personalized cancer vaccine shows promise in treating advanced kidney cancer; in a small study, nine patients with stage 3 or 4 kidney cancer remained cancer-free for an average of 34.7 months after receiving a vaccine tailored to their specific tumor type, triggering a significant immune resp...
Personalized Cancer Vaccine Shows Promise in Treating Advanced Kidney Cancer
A new personalized cancer vaccine shows promise in treating advanced kidney cancer; in a small study, nine patients with stage 3 or 4 kidney cancer remained cancer-free for an average of 34.7 months after receiving a vaccine tailored to their specific tumor type, triggering a significant immune resp...
Progress
40% Bias Score
Personalized Cancer Vaccine Shows Promising Results in Kidney Cancer Trial
A phase I trial at Dana-Farber Cancer Institute showed that a personalized cancer vaccine kept nine kidney cancer patients cancer-free for three years post-treatment; this is a significant advancement given the high recurrence rate of kidney cancer.
Personalized Cancer Vaccine Shows Promising Results in Kidney Cancer Trial
A phase I trial at Dana-Farber Cancer Institute showed that a personalized cancer vaccine kept nine kidney cancer patients cancer-free for three years post-treatment; this is a significant advancement given the high recurrence rate of kidney cancer.
Progress
40% Bias Score
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes showed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues but increased the risk of 19 others, highlighting both benefits and risks of this increasingly popular medication.
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes showed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues but increased the risk of 19 others, highlighting both benefits and risks of this increasingly popular medication.
Progress
36% Bias Score
Showing 37 to 48 of 54 results